CrossBridge Bio Awarded $15 Million CPRIT Grant to Advance CBB-120, Its Lead Dual-Payload ADC Targeting TROP-2, Into the Clinic
HOUSTON–(BUSINESS WIRE)–CrossBridge Bio, a biotechnology company pioneering next-generation dual-payload antibody-drug conjugates (ADCs) that have the potential to deliver safer, more durable responses for patients, including those resistant to approved ADC therapies, today announced it has…
